PPARG and Hepatic fibrosis: Farglitazar, an insulin-sensitizing agent, selectively binds and activates PPAR-γ and has no effect on liver fibrosis in patients with chronic hepatitis C infection, as manifested by no differences in the levels of alpha-smooth muscle actin (SMA) expression and collagen as well as histologic assessments after 52 weeks of treatment (McHutchison et al., 2010).